Literature DB >> 20227112

Detection of isocitrate dehydrogenase 1 mutation R132H in myelodysplastic syndrome by mutation-specific antibody and direct sequencing.

Mindaugas Andrulis1, David Capper, Thomas Luft, Christian Hartmann, Hanswalter Zentgraf, Andreas von Deimling.   

Abstract

Sequencing of the acute myeloid leukemia genome revealed somatic mutations in isocitrate dehydrogenase-1. Acute myeloid leukemia frequently develops from myelodysplastic syndrome. In order to test whether myelodysplastic syndrome also carries isocitrate dehydrogenase-1 mutations, we stained a series of bone marrow samples from patients with myelodysplastic syndrome using an antibody specific for the R132H mutation. Three out of 71 patients exhibited antibody binding to myeloid precursor cells. The presence of the R132H mutation was confirmed by DNA sequencing. We demonstrated that isocitrate dehydrogenase-1 mutations occur in myelodysplasia preceding acute myeloid leukemia and that the R132H alteration can be detected by immunohistochemistry. Copyright (c) 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20227112     DOI: 10.1016/j.leukres.2010.02.014

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  4 in total

1.  IDH1 R132H mutation is a rare event in myeloproliferative neoplasms as determined by a mutation specific antibody.

Authors:  Mindaugas Andrulis; David Capper; Jochen Meyer; Roland Penzel; Christian Hartmann; Hanswalter Zentgraf; Andreas von Deimling
Journal:  Haematologica       Date:  2010-06-09       Impact factor: 9.941

Review 2.  [Predictive molecular pathological stratification of hematological neoplasms].

Authors:  M Andrulis
Journal:  Pathologe       Date:  2016-11       Impact factor: 1.011

3.  Differential activity of NADPH-producing dehydrogenases renders rodents unsuitable models to study IDH1R132 mutation effects in human glioblastoma.

Authors:  Nadia A Atai; Nynke A Renkema-Mills; Joost Bosman; Nadja Schmidt; Denise Rijkeboer; Wikky Tigchelaar; Klazien S Bosch; Dirk Troost; Ard Jonker; Fonnet E Bleeker; Hrvoje Miletic; Rolf Bjerkvig; Philip C De Witt Hamer; Cornelis J F Van Noorden
Journal:  J Histochem Cytochem       Date:  2011-02-10       Impact factor: 2.479

4.  The emerging role of d-2-hydroxyglutarate as an oncometabolite in hematolymphoid and central nervous system neoplasms.

Authors:  Dinesh Rakheja; L Jeffrey Medeiros; Scott Bevan; Weina Chen
Journal:  Front Oncol       Date:  2013-07-02       Impact factor: 6.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.